Aldafermin (NGM 282), an engineered FGF 19 analog, demonstrated its safety and effectiveness in reducing liver fat content, improving liver fibrosis, and preventing the progression of non-alcoholic steatohepatitis (NASH) in a recent phase 2 randomized control trial [59], whereas its ability to improve insulin sensitivity remained inconsistent among studies [60]. This evidence concerns the gene FGF19 and Hepatic fibrosis.